Bavarian Nordic A/S (CPH:BAVA)

Denmark flag Denmark · Delayed Price · Currency is DKK
170.70
+2.05 (1.22%)
Jun 26, 2025, 4:59 PM CET
9.39%
Market Cap 13.29B
Revenue (ttm) 6.23B
Net Income (ttm) 1.32B
Shares Out 77.84M
EPS (ttm) 16.62
PE Ratio 10.27
Forward PE 11.09
Dividend n/a
Ex-Dividend Date n/a
Volume 133,317
Average Volume 229,578
Open 170.40
Previous Close 168.65
Day's Range 168.60 - 173.45
52-Week Range 123.30 - 300.00
Beta 1.20
RSI 47.12
Earnings Date Aug 22, 2025

About Bavarian Nordic

Bavarian Nordic A/S develops, manufactures, and supplies life-saving vaccines. The company offers non-replicating smallpox and monkeypox vaccines under the IMVAMUNE, IMVANEX, and JYNNEOS names; rabies vaccine for human use under the Rabipur/RabAvert name; tick-borne encephalitis vaccine under the Encepur name; Vaxchora, an oral vaccine for immunization against cholera; and Vivotif/Typhoral, an oral vaccine for immunization against typhoid fever. It is also developing MVA-BN WEV for the treatment of encephalitis viruses. It operates in the Unite... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 1992
Employees 1,605
Stock Exchange Copenhagen Stock Exchange
Ticker Symbol BAVA
Full Company Profile

Financial Performance

In 2024, Bavarian Nordic's revenue was 5.72 billion, a decrease of -19.06% compared to the previous year's 7.06 billion. Earnings were 987.98 million, a decrease of -33.03%.

Financial Statements

News

Bavarian Nordic Announces the Initiation of Clinical Trials of Mpox Vaccine in Infants and Pregnant Women

COPENHAGEN, Denmark, June 26, 2025 – Bavarian Nordic A/S (OMX: BAVA) announced today the initiation of the first of two clinical trials designed to support approval and use of the MVA-BN® mpox/smallpo...

23 hours ago - GlobeNewsWire

Bavarian Nordic Initiates Phase 3 Study of Chikungunya Vaccine in Children

COPENHAGEN, Denmark, June 12, 2025 – Bavarian Nordic A/S (OMX: BAVA) announced today the initiation of a Phase 3 clinical study of its single-dose, virus-like particle (VLP) chikungunya vaccine, CHIKV...

14 days ago - GlobeNewsWire

Bavarian Nordic A/S (BVNKF) Q1 2025 Earnings Call Transcript

Bavarian Nordic A/S (OTCPK:BVNKF) Q1 2025 Earnings Conference Call May 9, 2025 8:00 AM ET Company Participants Rolf Sass Sorensen - Head, Investor Relations Paul Chaplin - Chief Executive Officer Henr...

6 weeks ago - Seeking Alpha

Report of transactions of shares and related securities of Bavarian Nordic by persons holding managerial responsibilities and/or persons/companies closely associated with such

COPENHAGEN, Denmark, May 9, 2025 – Bavarian Nordic A/S (OMX: BAVA) has today received information about the following transactions of the Company's shares/related securities by persons holding manager...

6 weeks ago - GlobeNewsWire

Bavarian Nordic Announces Interim Results for the First Three Months of 2025

COPENHAGEN, Denmark , May 9, 2025 – Bavarian Nordic A/S (OMX: BAVA) announced today its interim financial results and business progress for the first three months of 2025.

6 weeks ago - GlobeNewsWire

Bavarian Nordic Awarded Contract Options from the U.S. Government for Production and Supply of Freeze-dried Smallpox/Mpox Vaccines

COPENHAGEN, Denmark, May 6, 2025 – Bavarian Nordic A/S (OMX: BAVA) announced today that the Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Pre...

7 weeks ago - GlobeNewsWire

Bavarian Nordic Receives Marketing Authorization for Chikungunya Vaccine for Persons Aged 12 and Older in the United Kingdom

COPENHAGEN, Denmark, May 2, 2025 – Bavarian Nordic A/S (OMX: BAVA) announced today that the UK Medicines and Healthcare products Regulatory Agency (MHRA) has granted marketing authorization in the Uni...

7 weeks ago - GlobeNewsWire

Bavarian Nordic's Chikungunya Vaccine Receives Recommendation from U.S. CDC's Advisory Committee on Immunization Practices (ACIP)

COPENHAGEN, Denmark, April 16, 2025 – Bavarian Nordic A/S (OMX: BAVA) announced today that the U.S. Centers for Disease Control and Prevention's (CDC) Advisory Committee on Immunization Practices (ACI...

2 months ago - GlobeNewsWire

Correction: Resolutions of the Annual General Meeting 2025 of Bavarian Nordic A/S

COPENHAGEN, Denmark, April 9, 2025 – Bavarian Nordic A/S (OMX: BAVA) today held the Annual General Meeting with the following results: The Annual Report for 2024 was adopted. The Board of Directors' p...

2 months ago - GlobeNewsWire

Resolutions of the Annual General Meeting 2025 of Bavarian Nordic A/S

COPENHAGEN, Denmark, April 9, 2025 – Bavarian Nordic A/S (OMX: BAVA) today held the Annual General Meeting with the following results: The Annual Report for 2024 was adopted. The Board of Directors' p...

2 months ago - GlobeNewsWire

Bavarian Nordic Trading At Great Value Levels With Upbeat 2025 Outlook

BVNKF now expects margin improvements from rabies/TBE vaccine production transfers to Denmark, starting in 2025. Also, their recently FDA-approved freeze-dried Jynneos vaccine and EU/US-approved chiku...

2 months ago - Seeking Alpha

Pharma tariff relief likely short-lived with sector-specific duties on the horizon

Pharmaceutical companies breathed a sigh of relief Wednesday after U.S. President Donald Trump revealed that they would not be subject to reciprocal tariffs — but that reprieve could prove fleeting. T...

3 months ago - CNBC

US FDA approves freeze-dried version of Bavarian Nordic's mpox, smallpox vaccine

Denmark's Bavarian Nordic said on Monday the U.S. Food and Drug Administration has approved a freeze-dried formulation of its mpox and smallpox vaccine.

3 months ago - Reuters

Bavarian Nordic Receives U.S. FDA Approval of Freeze-Dried Smallpox and Mpox Vaccine

COPENHAGEN, Denmark, March 31, 2025 – Bavarian Nordic A/S (OMX: BAVA) today announced that the U.S. Food and Drug Administration (FDA) has approved the freeze-dried formulation of JYNNEOS® (Smallpox a...

3 months ago - GlobeNewsWire

Widely used drugs on US imports list from Europe

Widely used prescription medicines could get caught up in the Trump administration's tariff trade wars and EU retaliation.

3 months ago - Reuters

Bavarian Nordic A/S – Notice Convening Annual General Meeting

COPENHAGEN, Denmark, March 12, 2025 – Pursuant to Articles 10-14 of the Articles of Association, the shareholders of Bavarian Nordic A/S are hereby convened to the Annual General Meeting to be held on

3 months ago - GlobeNewsWire

Bavarian Nordic Announces Acceptance of Marketing Authorization Application for Chikungunya Vaccine in the UK for Persons Aged 12 and Older

COPENHAGEN, Denmark, March 7, 2025 – Bavarian Nordic A/S (OMX: BAVA) announced today that the UK Medicines and Healthcare products Regulatory Agency (MHRA) has validated the marketing authorization ap...

3 months ago - GlobeNewsWire

Bavarian Nordic A/S (BVNKF) Q4 2024 Earnings Call Transcript

Bavarian Nordic A/S (OTCPK:BVNKF) Q4 2024 Earnings Conference Call March 5, 2025 8:00 AM ETCompany ParticipantsRolf Sass Sorensen - Head, Investor...

4 months ago - Seeking Alpha

Report of transactions of shares and related securities of Bavarian Nordic by persons holding managerial responsibilities and/or persons/companies closely associated with such

COPENHAGEN, Denmark, March 5, 2025 – Bavarian Nordic A/S (OMX: BAVA) has today received information about the following transactions of the Company's shares/related securities by persons holding manag...

4 months ago - GlobeNewsWire

Bavarian Nordic Publishes Annual Report 2024

Audited results confirm full-year revenue of DKK 5,716 million and EBITDA of DKK 1,603 million. Two new early-stage pipeline programs, Lyme disease and Epstein-Barr Virus (EBV), introduced.

4 months ago - GlobeNewsWire

Bavarian Nordic Receives Marketing Authorization in Europe for Chikungunya Vaccine for Persons Aged 12 and Older

COPENHAGEN, Denmark, February 28, 2025 – Bavarian Nordic A/S (OMX: BAVA) today announced that the European Commission has granted marketing authorization in Europe for VIMKUNYA® for active immunizatio...

4 months ago - GlobeNewsWire

Biological E in strategic pact with Danish co Bavarian Nordic to manufacture Chikungunya vax for global access

Hyderabad: Biopharma player Biological E (BE) entered into a strategic partnership with Danish vaccine maker Bavarian Nordic to manufacture the latter.

4 months ago - The Times of India

Bavarian Nordic Partners with Biological E Limited to Expand Global Access to Chikungunya Vaccine

COPENHAGEN, Denmark, February 25, 2025 – Bavarian Nordic A/S (OMX: BAVA) today announced a strategic partnership with Biological E. Limited (BE) to expand access to Bavarian Nordic's chikungunya vacci...

4 months ago - GlobeNewsWire